We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$285M
AUM Growth
+$33.9M
Cap. Flow
-$13.6M
Cap. Flow %
-4.76%
Top 10 Hldgs %
67.96%
Holding
105
New
6
Increased
8
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.84M
2
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$1.6M
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$890K
4
ZIMV
ZimVie
ZIMV
+$642K
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$515K

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$7.16M
2
VKTX icon
Viking Therapeutics
VKTX
+$2.17M
3
LK
Luckin Coffee Inc. American Depositary Shares
LK
+$2.11M
4
ICLO icon
Invesco AAA CLO Floating Rate Note ETF
ICLO
+$1.25M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$876K

Sector Composition

Rank Sector Weight
1 Healthcare 30.38%
2 Materials 27.67%
3 Financials 18.32%
4 Miscellaneous 10.77%
5 Communication Services 6.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLMT icon
1
Calumet Specialty Products
CLMT
$4.74B
$77.1M 27.08%
4,325,000
– –
APO icon
2
Apollo Global Management
APO
$77.8B
$28.1M 9.88%
225,000
– –
GOOG icon
3
Alphabet (Google) Class C
GOOG
$4.1T
$19.1M 6.71%
112,220
– –
AB icon
4
AllianceBernstein
AB
$3.42B
$16.7M 5.89%
48,000
-1,000
-2% -$34.2K
CLOZ icon
5
Panagram BBB-B CLO ETF
CLOZ
$798M
$14.6M 5.13%
542,868
– –
DCGO icon
6
DocGo
DCGO
$38.4M
$10.2M 3.58%
3,070,850
– –
ABBV icon
7
AbbVie
ABBV
$440B
$9.95M 3.5%
5,037
– –
PFE icon
8
Pfizer
PFE
$158B
$6.5M 2.28%
224,537
-24,200
-10% -$706K
AAPL icon
9
Apple
AAPL
$4.61T
$5.81M 2.04%
2,494
– –
VRNA
10
DELISTED
Verona Pharma
VRNA
$5.18M 1.82%
180,000
-23,000
-11% -$566K
OABI icon
11
OmniAb
OABI
$616M
$4.86M 1.71%
1,148,505
+30,000
+3% +$130K
ICLO icon
12
Invesco AAA CLO Floating Rate Note ETF
ICLO
$573M
$4.84M 1.7%
188,887
-48,866
-21% -$1.25M
ARDX icon
13
Ardelyx
ARDX
$973M
$4.71M 1.65%
682,867
-90,000
-12% -$531K
JPM icon
14
JPMorgan Chase
JPM
$940B
$4.42M 1.56%
20,985
– –
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$4.35M 1.53%
332,000
-1,000
-0.3% -$15.2K
JAAA icon
16
Janus Henderson AAA CLO ETF
JAAA
$30.4B
$4.32M 1.52%
84,829
+31,432
+59% +$1.6M
CPRX
17
DELISTED
Catalyst Pharmaceutical
CPRX
$4.21M 1.48%
212,000
– –
TVTX icon
18
Travere Therapeutics
TVTX
$6.23B
$3.61M 1.27%
258,231
-7,735
-3% -$80.6K
INZY
19
DELISTED
Inozyme Pharma
INZY
$2.95M 1.04%
564,549
– –
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.32B
$2.9M 1.02%
382,000
+67,693
+22% +$515K
XERS icon
21
Xeris Biopharma Holdings
XERS
$1.55B
$2.85M 1%
1,000,000
+180,000
+22% +$462K
GSK icon
22
GSK
GSK
$97.3B
$2.66M 0.93%
65,000
– –
IMVT icon
23
Immunovant
IMVT
$8.17B
$2.62M 0.92%
92,000
+500
+0.5% +$14.7K
VKTX icon
24
Viking Therapeutics
VKTX
$3.93B
$2.47M 0.87%
39,036
-37,000
-49% -$2.17M
CSX icon
25
CSX Corp
CSX
$90.8B
$2.42M 0.85%
70,000
– –
1
2 3 4 5

Similar funds

GFL
Granite FO LLC Bedford, New Hampshire $189M AUM 56.18% 1-Year Est. Return
SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FSBI
Fearless Solutions (Best Invest) San Antonio, Texas $189M AUM 32.69% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM

David M. Knott Jr's Q3 2024 Portfolio in Review

As of Q3 2024, David M. Knott Jr held 105 positions worth $285M, up 14% from $251M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

David M. Knott Jr withdrew a net $13.6M in Q3 2024, closing 13 positions and reducing 23 holdings. Its most notable exit was Ligand Pharmaceuticals, an estimated $7.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 31% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in BioMarin Pharmaceuticals worth $2.39M.

  • David M. Knott Jr's largest Q3 2024 buy was BioMarin Pharmaceuticals: 34,000 shares worth $2.39M.
  • David M. Knott Jr added most to Janus Henderson AAA CLO ETF in Q3 2024, an estimated $1.6M increase.
  • David M. Knott Jr's biggest Q3 2024 reduction was Viking Therapeutics, cutting an estimated $2.17M.
  • David M. Knott Jr fully exited Ligand Pharmaceuticals in Q3 2024, selling an estimated $7.16M.
  • David M. Knott Jr's ten largest holdings make up 68% of its $285M portfolio in Q3 2024.
  • David M. Knott Jr opened 6 new positions and closed 13 in Q3 2024.
  • David M. Knott Jr's portfolio value rose 14% quarter-over-quarter to $285M.

Based on David M. Knott Jr's 13F filing for Q3 2024, filed 13 Nov 2024.